NCT07332520Completed
Predicting Heart Failure Outcomes With Biomarkers and Imaging
Blood Biomarkers Combined With Imaging Parameters for Prognostic Assessment in Patients With Different Types of Heart Failure: A Retrospective Single-Center Cohort Study
Source: ClinicalTrials.gov · Last updated 27 Jan 2026
Brief summary (registry, in English)
This study aims to develop a better model to predict one-year risk of death in patients with heart failure. We will test whether combining information from routine blood tests (like NT-proBNP) and heart scans (measuring features like epicardial fat density) improves risk prediction compared to using either type of data alone. This is a retrospective study using existing medical records of patients treated for chronic heart failure at Xinjiang Medical University First Affiliated Hospital between 2012 and 2024. No new patient contact or interventions are involved. The goal is to enable more accurate, personalized risk assessment across different types of heart failure (HFrEF, HFmrEF, HFpEF).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 4000 (actual)
- First submitted
- 28 Dec 2025
- Start date
- 1 Jan 2012
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Xinjiang Medical University
- Diseases
- Heart failure
- NCT number
- NCT07332520
What you commit to
- Study type: Observational
- Participants enrolled: 4000
- From 1 Jan 2012 to the primary completion date, 31 Dec 2024
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Heart failure primarily due to severe primary valvular disease, acute myocardial infarction, myocarditis, or pulmonary embolism.
- End-stage renal disease requiring dialysis.
Other
- Clinical records or follow-up data are severely incomplete, precluding outcome assessment.
Who the study is looking for
- Age ≥ 18 years.
- Confirmed diagnosis of chronic heart failure.
- Treated at the study center between January 1, 2012, and December 31, 2024.
- Availability of both qualifying blood biomarker test results (NT-proBNP and/or high-sensitivity cardiac troponin) and cardiac imaging (echocardiography and/or cardiac CT) performed within a ±3-month window around the index encounter.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.